Robert Lorne Hopfner
CIK 1551966 · last filed 2025-12-22
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$94.93M
Companies
4
Total Filings
32
Lifetime Open-Market Net
$3.17M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EVMN | Director | 294,502 | $11.34 | $3.34M | $17.4K | 1 | 2025-12-22 |
| RLYB | Director | 211,798 | $16.11 | $3.41M | $7.50M | 7 | 2025-05-15 |
| Inozyme Pharma, Inc. (INZY) Delisted | Director | 2,923,110 | $4.00 | $11.69M | $16.20M | 11 | 2024-06-20 |
| PCVX | Director | 1,577,316 | $55.91 | $88.18M | -$20.55M | 11 | 2021-06-03 |
Recent Filings · Page 2 of 4
32 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-05-15 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +447,932 | $2.85M | EDGAR |
| 2023-03-30 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +344,592 | $1.56M | EDGAR |
| 2023-03-29 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +207,840 | $841.1K | EDGAR |
| 2022-06-14 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-26 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2022-04-20 | Inozyme Pharma, Inc. (INZY) Delisted | Buy (P) | +1,070,000 | $3.95M | EDGAR |
| 2022-01-05 | RLYB | Grant (A) | — | $0 | EDGAR |
| 2021-08-04 | RLYB | Mixed | +2,271,311 | $7.50M | EDGAR |
| 2021-06-24 | Inozyme Pharma, Inc. (INZY) Delisted | Grant (A) | — | $0 | EDGAR |
| 2021-06-03 | PCVX | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.